Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
33 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
AUSTRIA
WIEN
WIEN
REGO-SARC: Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy: a Multinational, Randomized, Phase II, Placebo-controlled Trial - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
GERMANIA
Berlin
BERLIN
PazoQol: Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial -DE-
Helios Klinikum Emil von Behring
Klinik für Onkologie
GERMANIA
Hessen
FRANKFURT AM MAIN
OlaReDo: Efficacy of Olaratumab and Rechallenge With Doxorubicin in Anthracycline Pretreated, Advanced Soft Tissue Sarcoma Patients. An Exploratory Phase-II Study
Krankenhaus Nordwest GmbH
Institut für Klinisch-Onkologische Forschung
IRLANDA
County Dublin
DUBLIN
European Paediatric Soft Tissue Sarcoma Study Group protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas 2005 (phase III) - IE
Children's Health Ireland @ Crumlin
National Oncology/ Bone Marrow Transplant Centre and Haematology Department
SPAGNA
Andalucía
SEVILLA
GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES
Hospital Universitario Virgen del Rocío
MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA)
SPAGNA
Andalucía
SEVILLA
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitario Virgen del Rocío
Unidad de Oncología Médica, Oncología Radioterápica y Radiofísica
SPAGNA
Cataluña
BADALONA
GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Oncología Médica
SPAGNA
Cataluña
BARCELONA
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPAGNA
Madrid
MADRID
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
SPAGNA
Madrid
MADRID
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitario La Paz
Servicio de Oncología Médica
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Gemcitabine andDocetaxel With or Without Olaratumab in the Treatment ofAdvanced Soft Tissue Sarcoma -GB
Institution: Information not provided - CH
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
PazoQol: Quality of life in patients with non-adipocyte soft tissue sarcoma underpalliative chemotherapy or pazopanib - a randomized, controlled trial - CH
Institution: Information not provided - CH
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
ANNOUNCE: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
FRANCIA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma (Phase II) - FR
Institution: Information not provided - FR
FRANCIA
AUVERGNE-RHONE-ALPES
LYON
Multicenter phase I/II study of continuous dosing of Sunitinib in non-GIST sarcomas with concomitant radiation therapy.
CLCC Léon Bérard
Radiothérapie
FRANCIA
NOUVELLE AQUITAINE
BORDEAUX
RADIOSARP : A Phase Ib Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANCIA
NOUVELLE AQUITAINE
BORDEAUX
TRAMUNE : Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas : A Phase Ib Study
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANCIA
NOUVELLE AQUITAINE
BORDEAUX
TARMIC : Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
GERMANIA
Baden-Württemberg
HEIDELBERG
Retro-Ion: Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion Prospektive Randomisierte Phase-II-Studie
Neurologische Universitätsklinik Heidelberg
Klinik für Radioonkologie und Strahlentherapie
GERMANIA
Nordrhein-Westfalen
KÖLN
EORTC 62072 (PALETTE) - A randomized, double blind phase III trial of Pazopanib versus Placebo in patients with Soft Tissue Sarcoma whose disease has progressed during or following prior therapy - DE
Universitätsklinikum Köln
Klinik I für Innere Medizin - AG Prof. Wendtner
SPAGNA
Comunidad Valenciana
VALENCIA
ANNOUNCE: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma - ES
Hospital Universitario y Politécnico La Fe
Servicio de Oncología Médica
SPAGNA
Madrid
MADRID
Randomized, double-blind, 3-arm trial to evaluate the impact of blood loss following administration of three tranexamic acid regimens in patients undergoing bone or soft tissue sarcomas (Phase III) - ES
IdiPAZ - Instituto de Investigación Sanitaria del Hospital Universitario La Paz
Unidad Central de Investigación Clínica y Ensayos Clínicos del Hospital La Paz
SVIZZERA
Suisse Alémanique
ST. GALLEN
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial
Kantonsspital St. Gallen
Klinik für Medizinische Onkologie und Hämatologie; Klinik für Neurologie
SVIZZERA
Suisse Romande
LAUSANNE
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial
Centre Hospitalier Universitaire Vaudois CHUV
Département d'oncologie
UNGHERIA
Észak-Alföld
DEBRECEN
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Debreceni Egyetem Klinikai Központ Onkológiai Intézet
Institute of Oncology
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
Sperimentazioni cliniche internazionali
SPAGNA
Cataluña
SANT QUINTÍ DE MEDIONA
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Gemcitabine andDocetaxel With or Without Olaratumab in the Treatment ofAdvanced Soft Tissue Sarcoma
Institution: Information not provided - US
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Institution: Information not provided - US
STATI UNITI
Kansas
LAWRENCE
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC.
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US